UNITED THERAPEUTICS Corp UTHR revenue by segment, product and geography
In its fiscal year ending 2025-12-31, UNITED THERAPEUTICS Corp reported revenue across 8 products and services; the largest, Tyvaso, was $1.88B (+15.9% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Tyvaso$1.88Bshare n/a+15.9% yoy
- Tyvaso DPI$1.29Bshare n/a+25.0% yoy
- Nebulized Tyvaso$586Mshare n/a-0.2% yoy
- Remodulin$527Mshare n/a-2.1% yoy
- Orenitram$497Mshare n/a+14.4% yoy
- Unituxin$227Mshare n/a-5.0% yoy
- Adcirca$30Mshare n/a+26.1% yoy
- Product And Service Other$24Mshare n/a+8.6% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$3.04B95.4%+10.9% yoy
- Outside the United States$146M4.6%+5.8% yoy
Members sum to the consolidated $3.18B for this period.
- Tyvaso$458Mshare n/a-1.9% yoy
- Tyvaso DPI$330Mshare n/a+9.2% yoy
- Orenitram$136Mshare n/a+12.3% yoy
- Nebulized Tyvaso$127Mshare n/a-22.3% yoy
- Remodulin$127Mshare n/a-8.4% yoy
- Unituxin$53.6Mshare n/a-7.9% yoy
- +2 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.